-
Simcere Pharma Appoints Zhou Gaobo as Chief Investment Officer
Time of Update: 2022-03-09
On January 17, Simcere announced the appointment of Zhou Gaobo as chief investment officer, responsible for the company's innovative drug investment and business expansion, new investment platform construction, and strategic planning and practice.
Before joining Simcere, Mr.
-
Is the future of Chinese medicine really beautiful?
Time of Update: 2022-03-09
Core content of the "Guiding Opinions on Medical Insurance Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine"Source: State Administration of Traditional Chinese Medicine website, Zhongkang Industrial Capital Research CenterFrom the core content of the "Guiding Opinions", it can be seen that traditional Chinese medicine medical services benefit the most from it.
-
This week, 11 new class 1 drugs were approved for clinical use!
Time of Update: 2022-03-09
According to an earlier press release from Bangshun Pharmaceuticals, OB756 is an oral selective JAK2 inhibitor independently developed by the company, which can exert therapeutic effects by targeting the kinase activity of JAK2 V617F and blocking the JAK/STAT signaling pathway .
-
Medical device exports fell by 31%, why?
Time of Update: 2022-03-09
Data source: General Administration of Customs of China, Zhongcheng Digital Division (formerly Zhongcheng Medical Equipment) Exports amounted to US$24 billion In 2021, China's exports of medical devices to countries along the "Belt and Road" totaled US$24.
-
The world's first!
Time of Update: 2022-03-09
Article source: Medical Cube InfoAuthor: PickupOn January 20, the drug clinical trial registration and information publicity platform showed that Hengrui Medicine registered the phase I clinical study of CD112R/TIGIT dual anti-SHR-2002, aiming to evaluate the candidate drug alone or in combination with other anti-tumor treatments in the late stage.
-
The State Food and Drug Administration has stepped up remote inspections, and another imported product has been suspended!
Time of Update: 2022-03-09
During the interview, the reporter learned that through the form of remote inspection recently, the State Drug Administration carried out inspection on the production process of JW LIFE SCIENCE CORPORATION's Fat Emulsion Amino Acid (17) Glucose (11%) Injection .
-
Keytruda/Lenvima Combination Phase 3 Trial Announces Full Results
Time of Update: 2022-03-09
Trial results met its dual primary endpoint of overall survival (OS) compared with chemotherapy in patients with advanced endometrial cancer treated with the anti-PD-1 therapy Keytruda in combination with the oral multi-receptor tyrosine kinase inhibitor Lenvima and progression-free survival (PFS) showed significant improvement .
-
TPO receptor agonist "roprostim" approved for marketing in China
Time of Update: 2022-03-09
According to public information, roprostim is a thrombopoietin (TPO) receptor agonist developed by Amgen, and Kyowa Kirin owns the development rights of this product in Greater China, South Korea, Singapore, Malaysia and other regions.
-
The Gansu Provincial Food and Drug Administration released the results of drug sampling inspection of 8 batches of drugs that did not meet the requirements
Time of Update: 2022-03-09
The drug does not meet the standard requirements .
Attachment: List of drugs that do not meet the standard requirements in the first phase of drug sampling in Gansu Province in 2022 (8 batches in total)
-
FDA Accepts Samsung Bioepis Humira Biosimilar sBLA Application
Time of Update: 2022-03-09
S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the high-dose 100 mg/mL formulation of Humira biosimilar SB5 (adalimumab-bwwd).
Reference source: FDA Accepts Samsung Bioepis' and Organon's sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
-
Ascletis PD-L1 monoclonal antibody approved by FDA
Time of Update: 2022-03-09
On January 17, Ascletis announced that the IND application for subcutaneous injection of PD-L1 antibody ASC22 (envolimumab) was approved in the United States for chronic hepatitis B.
ASC22 is a First-in-class subcutaneously injected PD-L1 antibody for functional cure of chronic hepatitis B.
-
Target PD-L1!
Time of Update: 2022-03-09
According to public information, RO7191863 is a liver-directed, PD-L1-targeting N-acetylgalactosamine (GalNac)-modified single-stranded oligonucleotide candidate drug, which is planned to be developed for the treatment of chronic hepatitis B.
-
The listing application of Kelun, a 100 million-level oral hypoglycemic drug, was approved, and Yangzijiang and Shiyao competed for the market
Time of Update: 2022-03-09
Figure 2: 2021E China Urban Physical Pharmacy Terminal Non-insulin Hypoglycemic Drugs Oral TOP20 Variety PatternSource: Minet.
The domestic generic drugs have been approved for marketing, which is expected to drive the overall sales of this variety.
-
Use the market mechanism to correct the falsely high drug prices
Time of Update: 2022-03-09
The executive meeting of the State Council held on January 10 made it clear that the centralized procurement of drugs and high-value medical consumables should be carried out in a normalized and institutionalized manner .
-
The CD39 monoclonal antibody of Kewang Pharma is approved for clinical use in China
Time of Update: 2022-03-09
By blocking the ATPase activity of the CD39 protein, ES002 can inhibit the production of adenosine while maintaining the level of extracellular ATP with pro-inflammatory effects, thereby creating an immune microenvironment conducive to anti-tumor .
-
Are the "Peier 13" selling well?
Time of Update: 2022-03-09
Before the domestic 13-valent pneumonia conjugate vaccine was launched, due to the strong demand and the monopoly of the product in the market, even if the price was high (698 yuan per dose), Peier has been in a state of short supply in the Chinese market, and there have been frequent "out of stock", Relevant statistics show that in 2019, Peier's batch issuance was 4.
-
China's first new crown oral drug VV116 is expected to apply for listing in the second half of the year
Time of Update: 2022-03-09
It was learned on January 17 that VV116, the only small molecule drug for the treatment of COVID-19 that has been approved for clinical trials in China, will start its NDA application as soon as it passes the clinical trials within the year .
-
Hengrui Medicine's Class 1 new drug Dalsili has been approved for marketing!
Time of Update: 2022-03-09
The approval of dalcilide this time is mainly based on the DAWNA-1 study: a multicenter, randomized, controlled, double-blind phase III clinical study, aiming to compare dalcilide with placebo plus fulvestrant in the treatment of previous endocrine therapy recurrence or advanced HR+/HER2- advanced breast cancer .
-
Huahai Pharmaceutical's Metoprolol Succinate Sustained-Release Tablets and Silodosin Capsules were approved by the US FDA
Time of Update: 2022-03-09
On January 6, Huahai Pharmaceutical issued an announcement saying that the abbreviated new drug application for metoprolol succinate sustained-release tablets and silodosin capsules submitted by the company to the US FDA has been approved .
-
The first domestic CD20 new drug!
Time of Update: 2022-03-09
Article source: Medical Cube InfoAuthor: PickupOn January 11, the CDE official website showed that the innovative CD20 monoclonal antibody zebetuzumab (R&D code: HS006, trade name: Enricix) independently developed by Borui Bio/Hisun Bio was used for initial treatment of CD20 positive The marketing application for the indication of diffuse large B-cell lymphoma (DLBCL) was accepted by the State Food and Drug Administration .
